In:
Cancer, Wiley, Vol. 122, No. 21 ( 2016-11), p. 3354-3362
Abstract:
The objective response rate of programmed cell death receptor 1 (PD‐1)–based therapy in patients with acral and mucosal melanoma is 32% and 23%, respectively, which is similar to published rates in cutaneous melanoma. These data support the routine use of PD‐1–based therapy for patients with these rare melanoma subtypes. See also pages 000‐000 and 000‐000.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v122.21
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink